



Lessening Organ
Dysfunction with
VITamin C

LOVIT and LOVIT-C  **VID**

Newsletter

Volume 4, Issue 2 – June 15, 2022

Dear LOVIT Team

The results of the LOVIT trial were presented today at the Critical Care Reviews meeting in Belfast, and the manuscript was simultaneously published in New England Journal of Medicine (<https://www.nejm.org/doi/full/10.1056/NEJMoa2200644>). An updated systematic review is published in NEJM Evidence (<https://evidence.nejm.org/doi/full/10.1056/EVIDoa220010>).

The study showed that participants in the vitamin C group had a higher risk of death or persistent organ dysfunction at 28 days, compared to participants who received placebo. At day 28, 191 of 429 participants (44.5%) in the vitamin C group had died or had persistent organ dysfunction, as compared with 167 of 434 participants (38.5%) in the placebo group.

The results were not what we hypothesized; however, they are extremely important for patient care. Clinical trials like LOVIT are vital for examining currently used interventions and providing evidence on which treatments are effective and which are harmful.

We thank you again for your extremely important work in LOVIT.

Thank you!!!

We LOV(ed) working with you!


LOVIT-C VID Trial

After reviewing final data from LOVIT and data so far from LOVIT-COVID, the DSMB has recommended continued enrollment in LOVIT-COVID.

Enrollment will continue until we reach the pre-specified sample size of n=800, or until the combined analysis with the REMAP-CAP vitamin C domain and LOVIT-COVID meets the pre-specified stopping criteria, whichever comes first.

13 sites are activated and 390 participants have been enrolled.
We ask sites to enter data and to address queries in a timely manner.

LOVIT-COVID Patients enrolled / month as of June 14, 2022



Enrollment

Sunnybrook HSC	131	Ottawa General Hospital	14
CIUSSS de l'Estrie – CHUS	115	Royal Victoria Health Centre	9
St-Joseph's Healthcare Hamilton	46	Royal Alexandra Hospital	5
Niagara Health	28	CHUM	5
CHU de Québec – Université Laval	16	Ottawa Civic Hospital	4
Hamilton General Hospital	14	Juravinski Hospital	3

We are still accepting sites that wish to participate

START-UP PAYMENT: \$3000 for sites submitting through CTO or MSSS and \$4000 for other sites.

Please contact us if you have questions

Marie-Hélène Masse
Project leader
1-819-346-1110 ext. 14173
marie-helene.masse3@usherbrooke.ca

Julie Ménard
Co-Project leader
1-819-346-1110 ext. 13534
julie.menard.ciusse-chus@ssss.gouv.qc.ca

Visit our website: <http://lovit.cctg.ca/>